Search PubMed⌕ Search

Biomedical subjects

I A Eide

Publications and source records attributed to I A Eide.

2 recordsLinked to original sources
PubMed2001

[Urinary problems and prostate-specific antigen in a Norwegian normal population].

BACKGROUND: Measurements of PSA in serum is crucial in the diagnostic work-up of prostatic diseases. MATERIAL AND METHODS: We have studied the distribution of PSA values in an unselected population of 609 men, and the relation between PSA level and urinary symptoms, age and prostate volume. RESULTS: 87 (14%) men had a PSA concentration at or above the reference value of 4.0 ng/ml. Prostate cancer was verified in 14 (16%) of these men. The probability of having PSA equal to or above 4.0 ng/ml was 12 times greater for men with a prostate volume of 40 cm3 or less than for men with a prostate volume less than 20 cm3. Mean PSA values were higher in men with severe than with mild urinary symptoms, but symptoms were poor predictors of PSA levels. Age was not associated with an increase in PSA level independent of prostate volume. INTERPRETATION: Absence of urinary symptoms does not exclude elevated PSA values and thus not cancer. Most men with PSA equal to or above 10.0 ng/ml will have prostate cancer, but enlarged prostate without cancer can also give elevated PSA values.

Aged↗
PubMed2000

[Prostate-specific antigen].

BACKGROUND: Serum PSA has been commercially available for more than ten years, and has proved to be the most important tumour marker for prostate cancer. We review the clinical usefulness and limitations of serum PSA as a tumour marker of prostate cancer. MATERIAL AND METHODS: The international literature and medical databases were searched for studies on the contributions and limitations of PSA in clinical practice. RESULTS: Serum PSA > or = 4.0 ng/ml is commonly regarded as elevated, and give rise suspicion of prostate cancer. However, only one out of four men with serum PSA level between 4.0 ng/ml and 10.0 ng/ml has prostate cancer. The most common cause of elevated serum PSA value in this group is benign prostatic hyperplasia. In an attempt to increase the sensitivity as well as the specificity for serum PSA in the detection of prostate cancer, the serum PSA level has been combined with age of patients (age-specific serum PSA), time (PSA velocity), prostate volume (PSA density), different molecular PSA forms, like per cent of free PSA. Some of these new methods have shown promising results. INTERPRETATION: PSA is the best and most widely used tumour marker in urology. However, it is important that clinicians know the limitations of this marker.

Age Factors↗